The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Fusion protein Ag85B-MPT64(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice.
Yu Luo; Bingxiang Wang; Lina Hu; Hongjuan Yu; Zejiao Da; Wenwen Jiang; Nannan Song; Yaqing Qie; Honghai Wang; Zhijiao Tang; et al. (Profiled Author: Ying Zhang)
Lanzhou Center for Tuberculosis Research & Institute of Pathogenic Biology, School of Basic Medical Sciences, Lanzhou University, China.
Tuberculosis (TB) remains a major infectious disease worldwide despite chemotherapy and BCG vaccine. The efficacy of the current TB vaccine BCG varies from 0 to 80%. New vaccines that have better protection than BCG or have the capability to boost BCG-primed immunity are urgently needed. We have previously constructed a fusion protein Ag85B-MPT64(190-198)-Mtb8.4 (AMM). In this study, we investigated the immunogenicity of the fusion protein AMM in a novel adjuvant of dimethyl-dioctyldecyl ammonium bromide and BCG polysaccharide nucleic acid (DDA-BCG PSN), and its capacity to boost BCG-primed immunity. The anti-Ag85B antibodies IgG1 and IgG2a were determined using ELISA and the number of spleen cells secreting IFN-gamma was determined by ELISPOT. In addition, the ability of the subunit vaccine AMM to boost BCG-primed immunity against Mycobacterium tuberculosis was analyzed. The fusion protein AMM induced more effective humoral and cell-mediated immune responses in mice than Ag85B alone. Mice primed with BCG vaccination followed by boosting with AMM produced a stronger immune response and afforded a better protection against M. tuberculosis infection than mice immunized with BCG alone or BCG priming followed by boosting with Ag85B. These findings suggest that AMM is a promising candidate subunit vaccine to enhance the protective efficiency of BCG.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Hongxia Niu; Lina Hu; Qing Li; Zejiao Da; Bingxiang Wang; Kefeng Tang; Qi Xin; Hongjuan Yu; Ying Zhang; Yong Wang; et al.Vaccine 2011;29(51):9451-8.
Jiazhen Chen; Sen Wang; Ying Zhang; Xiaodi Su; Jing Wu; Lingyun Shao; Feifei Wang; Shu Zhang; Xinhua Weng; Honghai Wang; et al.BMC infectious diseases 2010;10():273.
Jiazhen Chen; Xiaodi Su; Ying Zhang; Sen Wang; Linyun Shao; Jing Wu; Feifei Wang; Shu Zhang; Jiuling Wang; Xinhua Weng; et al.Microbes and infection / Institut Pasteur 2009;11(10-11):876-85.
Appears in this Publication
Author of this Publication